The Socioeconomic Impact of Cervical Cancer in the UK

By Staff Writer

March 7, 2024

Introduction

The socioeconomic impact of cervical cancer in the UK is a significant concern and the fourth most common cancer type globally among women. This article, based on a report from the Office of Health Economics (OHE), quantifies that burden and the potential savings from reaching the World Health Organisation’s (WHO) elimination target set in 2020. Currently the disease burden in the UK is more than twice the WHO target of less than 4 cases per 100,000 women.

The Cost of Cervical Cancer

Cervical cancer carries an estimated lifetime cost of £208,086 per case in the UK. This value includes direct healthcare expenses, individual patient costs, and broader societal costs (Figure 3) due to morbidity and mortality. The strain primarily falls on society and families, accounting for 85% of the total burden, with the healthcare system bearing just 8%. The primary factor influencing the overall cost throughout an individual person’s lifetime is the reduction in productivity (Figure 1), amounting to £130,984. This accounts for 63% of the individual burden and is mostly caused by the economic impact of mortality due to cervical cancer.

Figure 1. Lifetime socioeconomic cost per newly diagnosed patient

OOP= Out of pocket

The Socioeconomic Impact of Cervical Cancer in the UK

The total socioeconomic burden of new cervical cancer cases in the UK, at the current incidence rate of 9.7 cases per 100,000, is approximately £691 million. To put this into perspective, this burden equates to about 40% of the UK’s combined spending on immunisation and early detection programmes pre-COVID-19 (£1.7 billion in 2019) or about 8% of the total UK pre-COVID-19 spending on preventative care (£8.3 billion in 2019).

The Potential Savings

If the WHO elimination target were achieved today, there would be an instant 59% reduction in the socioeconomic burden, equivalent to about £406 million. The UK could save around £2.6 billion (Figure 2) compared to taking no action on cervical cancer elimination by achieving the WHO elimination threshold by 2046. This means that the socioeconomic burden of cervical cancer is preventable. However, these savings do not consider the cost required to achieve elimination, such as spending on prevention and control measures like vaccination and screening.

Figure 2. Achieving the WHO elimination target in the UK by 2046 could save £2.6 billion

The Path to Elimination

Achieving elimination requires a comprehensive action plan from the National Health Service (NHS) to overcome barriers to access, education, and awareness while maintaining adequate funding and resources. NHS England’s recent commitment to eliminate cervical cancer by 2040 provides the impetus to improve vaccination and screening coverage and implement a clear strategy to accelerate elimination.

Figure 3. Framework of cervical cancer socioeconomic burden

* Productivity loss quantifications already include tax returns due to workplace absenteeism.

Conclusion

In conclusion, the socioeconomic burden of cervical cancer in the UK, emphasises the urgency for effective intervention strategies to achieve the WHO elimination target by 2046, compared to taking no action. However, these savings must be weighed against the costs of implementing such strategies, including vaccination and screening programs. Therefore, it is crucial for health economists and policymakers to conduct further cost-effectiveness analyses to determine the optimal allocation of resources.

Reference url

Recent Posts

UK Pharmaceutical Pricing Analysis: Impasse in VPAG Review Undermines Patient Access and Market G...

By Staff Writer

August 25, 2025

The accelerated review of the UK's Voluntary Scheme for Branded Medicines Pricing, Access, and Growth (VPAG) concluded without agreement in August 2025. The review focused on soaring payment rates. These require companies to pay up to 35.6% of their revenue from NHS sales. Despite good faith effo...
EFPIA Response to Tariffs: Concerns Over U.S.-EU Trade Agreement Impact on Pharma Industry

By Staff Writer

August 22, 2025

The European Federation of Pharmaceutical Industries and Associations (EFPIA) has expressed significant concern over the new U.S.-EU Joint Framework Agreement. It is particularly worried about potential tariffs of 15% on pharmaceutical products. The organization argues these tariffs break a three...
TAVI Cost-Effectiveness in Brazil: Balancing Coverage Expansion and Economic Viability

By Staff Writer

August 21, 2025

The focus on TAVI cost-effectiveness Brazil has gained attention. The country is assessing the expansion of coverage for transcatheter aortic valve implantation (TAVI). This would include patients with severe aortic stenosis who are classified as low surgical risk (STS-PROM <4%) as a first-lin...